MedTrace Logo

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

NCT03361319 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2020-11-24

No results posted yet for this study

Summary

A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO IN RELAPSED NSCLC ADENOCARCINOMA

Conditions

  • NSCLC, Recurrent
  • Adenocarcinoma of Lung

Interventions

DRUG

Vargatef

small molecule triple kinase inhibitor

DRUG

Abraxane

Paclitaxel formulated as albumin bound nanoparticles

OTHER

placebo

Placebo in place of Ninedanib

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Celgene

    collaborator INDUSTRY

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Sanjay Popat · Royal Marsden NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2023-07-31
Completion
2023-07-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03361319 on ClinicalTrials.gov